PRESS-RELEASE filed May 19, 2026 at 08:00 ET
Artiva Biotherapeutics appointed Diego Miralles, M.D., as President and Head of R&D. Dr. Miralles brings >20 years of drug development experience including FDA approvals (PREZISTA, INTELENCE) and leadership at J&J Innovation, Vividion, and Laronde. He has served on Artiva's board since May 2024. The appointment is accompanied by an inducement grant of 232,500 options + 77,500 RSUs. The company is advancing AlloNK in autoimmune diseases and preparing for a Phase 3 registrational trial in refractory RA, with FDA alignment on a registrational path and a planned BLA submission in 2029. This is a clinical-stage biotech ($228M market cap) with no approved products and minimal revenue, the hire adds credibility but does not change the fundamental risk profile.